Key result
Oral tedisamil protected against ischemia-induced ventricular fibrillation in a post-infarction canine model, with 70% survival compared to 28.6% in the vehicle group (P <.05).
Why the study?
Does tedisamil prevent ischemia-induced ventricular fibrillation in a conscious canine model of sudden cardiac death?
Does tedisamil prevent ischemia-induced ventricular fibrillation in a conscious canine model of sudden cardiac death?
Absolute Event Rate: 70% vs 28.6%
p-value: p=<.05
Oral administration of tedisamil provides protection from ischemia-induced ventricular fibrillation in a post-infarction conscious canine model, likely by prolonging the ventricular effective refractory period.
No takes yet. Share an insight, caveat, or question.
Should not inform clinical VF prevention; hypothesis-generating for tedisamil in post-infarction models.
Friedrichs et al. (1996) studied Sudden cardiac death (post-myocardial infarction) (n=24). Tedisamil vs. Placebo/vehicle was evaluated on Survival from ischemia-induced ventricular fibrillation (p=<.05). Oral tedisamil protected against ischemia-induced ventricular fibrillation in a post-infarction canine model, with 70% survival compared to 28.6% in the vehicle group (P <.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: